INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
INSMED Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$95.29−0.98 (-1.02%)
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
Insmed statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Insmed | Industry median |
|---|---|---|
| Market Cap | $20.81B | $197.05M |
| Enterprise Value | $20.19B | $106.56M |
| PS Ratio | 18.29 | 3.93 |
| PB Ratio | 27.47 | 2.14 |
| P/TBV Ratio | 39.42 | 2.46 |
Enterprise value
| Measure | Insmed | Industry median |
|---|---|---|
| EV / Sales | 17.75 | 2.69 |
Income (trailing twelve months)
| Measure | Insmed | Industry median |
|---|---|---|
| Revenue | $1.14B | $57.94M |
| Gross Profit | $949.42M | $90.47M |
| Operating Income | -$840.62M | -$21.44M |
| Pretax Income | -$869.11M | -$14.45M |
| Net Income | -$875.31M | -$22.46M |
| EBITDA | -$840.62M | -$16.91M |
| EPS (Diluted) | -$4.11 | -$0.83 |
Margins
| Measure | Insmed | Industry median |
|---|---|---|
| Gross Margin | 83.5% | 52.3% |
| Operating Margin | -73.9% | -44.5% |
| Pretax Margin | -76.4% | -13.0% |
| Profit Margin | -76.9% | -39.2% |
| EBITDA Margin | -73.9% | -31.3% |
| FCF Margin | -71.0% | -8.85% |
Returns
| Measure | Insmed | Industry median |
|---|---|---|
| Return on Equity (ROE) | -87.2% | -53.1% |
| Return on Assets (ROA) | -38.2% | -41.0% |
| Return on Invested Capital (ROIC) | -1840.3% | -32.0% |
| Return on Capital Employed (ROCE) | -50.5% | -37.8% |
Growth
| Measure | Insmed | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 185.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 35.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 29.8% | 6.42% |
Balance sheet
| Measure | Insmed | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.16B | $62.42M |
| Total Debt | $543.51M | $120.13M |
| Net Cash (Debt) | $616.80M | $15.68M |
| Net Cash Per Share | $2.82 | $0.65 |
| Equity (Book Value) | $757.49M | $48.79M |
| Book Value Per Share | $3.47 | $1.36 |
| Tangible Book Value | $527.90M | $23.06M |
| Working Capital | $1.20B | $75.77M |
Financial position
| Measure | Insmed | Industry median |
|---|---|---|
| Current Ratio | 3.72 | 3.30 |
| Quick Ratio | 3.14 | 2.39 |
| Debt / Equity | 0.72 | 0.51 |
| Interest Coverage | -10.34 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Insmed | Industry median |
|---|---|---|
| Operating Cash Flow | -$778.92M | -$12.35M |
| Capital Expenditures | -$28.75M | -$1.06M |
| Free Cash Flow | -$807.67M | -$20.28M |
| FCF Per Share | -$3.70 | -$0.41 |
Efficiency
| Measure | Insmed | Industry median |
|---|---|---|
| Asset Turnover | 0.50 | 0.38 |
| Inventory Turnover | 1.51 | 2.67 |
| Revenue Per Employee | $683.68K | $398.96K |
| Profits Per Employee | -$526.03K | -$732.08K |
| Employee Count | 1,664 | 73 |
Dividends and yields
| Measure | Insmed | Industry median |
|---|---|---|
| Earnings Yield | -4.21% | -21.2% |
| FCF Yield | -3.88% | -7.64% |
Shares
| Measure | Insmed | Industry median |
|---|---|---|
| Shares Outstanding | 218,382,000 | 59,128,900 |
| Shares Change (YoY) | 18.7% | 11.1% |
| Shares Change (QoQ) | 0.81% | 0.54% |
| Float | 216,454,000 | 48,744,500 |
| Shares Held by Insiders | 0.88% | 11.8% |
| Shares Held by Institutions | 102.5% | 59.4% |
Taxes
| Measure | Insmed | Industry median |
|---|---|---|
| Income Tax | $6.21M | $91.50K |
Scores
| Measure | Insmed | Industry median |
|---|---|---|
| Altman Z-Score | 5.32 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Insmed's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.